Rating rising for Bb Biotech, the investment fund specializing in biotechnology companies. West LB Panmure in fact raised its recommendation from “outperform” to “buy” given the defensive nature of its holdings in American companies. The title is currently suspended due to the excessive burden of U.S. participation has recommended a freeze on prices.